Rhode Island College

Digital Commons @ RIC
Honors Projects Overview

Honors Projects

May 2022

Understanding the effects of N-terminal acetylation on the
oligomeric state of Tau
Miguel Jose Martinez Guzman

Follow this and additional works at: https://digitalcommons.ric.edu/honors_projects
Part of the Life Sciences Commons

Recommended Citation
Martinez Guzman, Miguel Jose, "Understanding the effects of N-terminal acetylation on the oligomeric
state of Tau" (2022). Honors Projects Overview. 211.
https://digitalcommons.ric.edu/honors_projects/211

This Honors is brought to you for free and open access by the Honors Projects at Digital Commons @ RIC. It has
been accepted for inclusion in Honors Projects Overview by an authorized administrator of Digital Commons @
RIC. For more information, please contact digitalcommons@ric.edu.

Understanding the effects of N-terminal
acetylation on the oligomeric state of
Tau

An undergraduate project presented
By Miguel Martinez-Guzman
To the Biology Department

April 2022
Rhode Island College

Faculty Advisor: William M. Holmes, Ph.D.

1

ABSTRACT: Microtubule-associated protein Tau (MAPT) is a protein that is associated with
dementias of the nervous system. These diseases are characterized by the abundance of Tau that is
hyperphosphorylated and has aggregated into insoluble fragments. The post translational
modification (PTM) mechanisms that regulate Tau are not working properly, and this protein has
become pathogenic. In its functional state, Tau supports structural components used for transport
most research on
phosphorylation. Tau is affected by PTMs such as acetylation, phosphorylation, and
ubiquitination, N-terminal (Nt) acetylation is one such modification, the most common
PTMs, with 80% of proteins humans modified this way. However, the effects that this
modification has on each protein varies, so although it affects Tau it is not clear how. Bacteria
cannot normally modify proteins post-translationally. However, with an Escherichia coli coexpression system that provides bacteria with the N-terminal acetyltransferases to acetylate the
protein they create, it is possible to produce modified protein for study. Using fast protein liquidchromatography to isolate the protein from bacteria, we can then use analytical techniques such as
nuclear magnetic resonance (NMR), native polyacrylamide gel electrophoresis (PAGE), and
Western blots will allow us to view the effects that Nt-actetylation has on the oligomerization rate
and structure of Tau. Further elucidating the effects of N-terminal acetylation on Tau provides
structural information about the use of the extreme N-terminus that is seen in microtubule binding
proteins, and possibly grant a physiological marker for neurodegenerative diseases.
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INTRODUCTION:
I. Dementia and Neurodegenerative Diseases
million people worldwide suffering from it (WHO 2021). Characterized by a decline in mental health
factors such as memory, learning, or social skills at a more rapid pace that is normally seen with age
(Budson and Solomon
becoming old
are character
act mechanism by which many of
these neurodegenerative diseases operate through is unknown, enough information has been amassed
concerning them to be able to identify either proteins of interest to study the disease, or in some cases even
some genetic markers that mean an individual is predisposed to develop the disease later in life (Nikolac et
al. 2019).
Some
of
the
most
common
neurodegenerative
diseases
are Huntington's
disease, Parkinson's disease
chronic traumatic encephalopathy, tauopathies,
and multiple sclerosis. Despite this, neurodegenerative diseases display different symptoms and their
prevalence among different populations varies, there are some commonalities within this family of diseases
that allow for common research threads between them. All these diseases involve disruption of
the protestasis network within the body, with each of them showing abnormal protein function in some way
(Rubinsztein 2006). This gives a common thread through which they can all be
researched through; information regarding abnormal protein homeostasis provides information for a
variety of diseases.
Generally considered to be incurable because of the limited ability (or lack thereof) of neuronal cell
recovery (Huebner and Strittmatter 2009), research in prevention of the diseases or being able
age would be a significant step in helping treatment and prevention of these diseases.
A. Chronic Traumatic Encephalopathy
Chronic Traumatic Encephalopathy(CTE) is a neurodegenerative disease that has been linked to
repeated brain trauma (Ridler 2017). Its symptoms include cognitive impairment, changes in mood, and
reduction in motor abilities. In the brain, this is shown off by a decrease of brain mass because of atrophy
in the medial temporal lobe and frontal and medial cortices (Baugh et al. 2012). These symptoms do not
show themselves immediately, and instead develop over an extended period. Originally being discovered
in the early 20th
-drunk. Although this term was
quickly phased out because of it trivializing the serious neurodegenerative disorder that was afflicting the
boxers and replaced with dementia pugilistica. In the modern day, this disease continues to plague boxers,
but it can be found in athletes and military veterans because of the tendencies for these individuals to suffer
concussive trauma (Maroon et al. 2015).
Currently, there is no treatment or prevention for CTE. As it is linked to repeated brain trauma, the
most effective treatment of it is currently to avoid successive trauma after initial injury, but there is no
pharmaceutical or physical intervention to help with its symptoms. There are currently no reliable methods
of being able to diagnose CTE before death, with the standard method of detection being observations made
on a brain after autopsy. CTE shares symptoms with other neurodegenerative diseases, further
compounding the difficulty in diagnosis (Askenes et al. 2017).

eventually progresses to language issues, failure to regulate mood, and reduction in language capabilities
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(Knopman et al. 2021). Diagnosis uses these symptoms along with patient family history, medical history
et al. 2006), Because of the similarities to other neurodegenerative
diseases, a diagnosis by exclusion may be used as well, ruling out other diseases until AD is the only viable
exclude the symptoms from other kinds of dementia, but these techniques are currently reserved for clinical
trials. It is the most prevalent form of dementia in the world, making up 60-70% of all cases (Simon et al.
2018). AD is a mysterious disease, with its causes being mostly unknown, and as such ways to prevent the
disease are unknown as well.
Although some research points to diet, exercise, pharmaceuticals, or education have been shown to
help prevent AD, none of this data is conclusive and is too inconsistent to prescribe to patients that are in
danger of developing the disease. Treatment for AD is in a similar state, with there being no cure for the
disease, and most treatments seeking to alleviate symptoms instead of preventing further neurodegeneration
or remission (McDade et al. 2021).
C. Huntington's Disease
enerative disease. HD
begins with minor changes in mood and mental capabilities, and then develops into movement disorders
resulting in need for long term care until the eventual death of the patient (NIH 2015). The symptoms appear
at around 30 to 40 years old for normal HD, or earlier for Juvenile AD. After onset of symptoms, patients
typically pass within 10 years.
The mutation that results in the disease is present on the HTT gene that codes for the Huntington
protein (Dayalu and Albin 2015). In the wild type version of the protein, it contains a series of around 35
cytosine-adenine-guanine (CAG) repeats. However, there exists a CAG repeat domain expansion of the
protein that results in a change of the conformation of the protein that increases its propensity to aggregate
and leads to eventual formation of the disease (Walker 2007). Normally individuals with the disease are
heterozygotes with only one copy of the mutant gene, but there have been reports of homozygous mutants
that show worse and earlier symptoms (Squitieri et al. 2003). Although the function of the protein is not
well known, it is assumed to have some function with axonal transport (Vitet et al. 2020). Although there
are treatments to help with the symptoms of the disease, it is a terminal illness and after its appearance
seldom can be done outside of palliative care to make the patient as comfortable as possible.

neurodegenerative disease that occurs because of the death of
dopaminergic neurons. It attacks the central nervous system (CNS) (Kalia and Lang 2015). It is the second
most ordinary form of dementia (Yao et al.
expresses itself
trembling. As further degradation of the CNS occurs, more issues begin to arise, such as trouble eating,
sleeping, talking and the development of depression (Kalia and Lang 2015).
Although PD is known to result because of the death of dopaminergic neurons, it is unclear through
what mechanism the neurons die (NIH 2021). Although there is some controversy in the field as to what is
a definit
-synuclein aggregation in the form of Lewy bodies (SchulzSchaeffer 2010). Lewy bodies are clumps of protein within the brain that interfere with normal brain
function and are considered the pathological biomarker for the disease.
Diagnosis of the disease is difficult, but the most reliable method of doing so has been to look at
protein biomarkers such as dopamine metabolites and amino acids within the cerebrospinal fluid and blood
serum. Medical imaging techniques also exist that can be used to help with the diagnosis, the deciding
factor is blood tests and neurological evaluations (Armstrong and Okun 2020). Although we can identify
the disease, the cause of it is still unknown. It is assumed that the disease is caused by a variety of
environmental and familial factors. There is promising evidence to suggest that PD can exist as an inherited
disease, with 15% of those afflicted having a relative with PD as well (Quadri et al. 2018).
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There are currently no cures for PD because of the complicated onset of the disease, but there does
exist pharmaceutical and surgical methods to reduce symptoms. In most cases surgical methods like Deep
Brain Stimulation are avoided because of the risks associated with them, but in severe cases it is considered.
Dopaminergic drugs are prescribed to assist with symptoms because the disease results from an irregularity
of dopamine in the brain, but because dopamine cannot pass the blood-brain barrier and must be provided
in a secondary manner. Drugs such as Levodopa, COMT inhibitors and dopamine agonists along with
exercise are often prescribed as treatment (Armstrong Okun 2020).
II. Tau Structure and Function
th
et al.
within the axons of the brain. Microtubules are important structural components of cells (Kapitein and
Hoogenraad
ellular transport (Chaudhary et al. 2018). Tau strengthens
its C-

ed down,

association with microtubules is dynamic, and it is regulated by post-translation modifications. Specifically,
Tau can be phosphorylated on several of its residues, and this results in a lowering of its affinity to
Alonso et al. 2018). However,
hyperphosphorylation of the protein results in aggregation (Wang et al. 2013).Upon hyperphosphorylation,
Tau is unable to bind with microtubules and instead forms Neurofibrillary Tangles (NFTs). These
the brain and does not allow for normal axonal function (Wang et al. 2013)
Because Tau is also no longer strengthening the microtubules as it does in its native state, the microtubules
in the brain begin to degrade as well (Cowan et al.2010) , resulting in the loss of a major structural
component of axons. The effect of phosphorylation on the protein clearly indicates that post-translation
modifications have a large effect on Tau.
Tau lacks a tertiary structure, being an intrinsically disordered protein. The single gene that encodes
for Tau is located on chromosome 17 in humans and is named MAPT (Microtubule associated protein
Tau). Alternative splicing results in six different isoforms of the protein, each distinguished by containing
or lacking exons 2, 3, and 10 (Avila et al.
off the longest isoform of the protein, containing the N-terminal projection domain, the proline rich region,
a microtubule binding domain, and a C-terminal domain. (Himmler et al. 1989). Because of this, the fulllength protein is not required when conducting studies on the function of the protein or its activity in
different conditions because it is assumed that the clinically relevant sections of the protein are involved
with binding. However, as tauopathies are caused by abnormal oligomerization of Tau, research on the
protein is focused on the C-terminal microtubule binding region of Tau that is involved with this
abnormal oligomerization and this is also the region that is involved in microtubule interaction. This leads
to other parts of the protein being understudied, while these ignored parts of the protein may serve some
purpose.
A. Tau Function
Tau in humans is found primarily in neurons (Cleveland 1977). Inside of neurons, Tau plays a
structural support role by assisting microtubules. Microtubules are tubulin polymers in the cytoskeleton of
eukaryotic cells that provide rigidity (Ledbetter and Porter 1963). Tau interacts with microtubules by
lowering the depolymerization rate, resulting in an increased growth rate and decreased degradation. The
protein can exist in dendrites, but it is believed to be toxic (Hall et al. 2001). Dendritic cells are instead
strengthened by the other main microtubule associated protein, MAP2 (Kalcheva et al. 1995)
Tau knockout mice do not display abnormal brain development and did not show an overtly
deficient phenotype (Wang and Liu 2008) implying that Tau may not be an integral protein in microtubule
stabilization, serving a redundant role along with other microtubule associated proteins. However, Tau KO
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mice display lower muscle strength and psychological capability as they aged (Ikegami et al. 2000),
implying that there is a role that other microtubule associated proteins cannot fill, or that Tau plays a
regulatory role in maintaining brain function. Tau is regulated reversibly by the presence of phosphate
groups, the addition or subtraction of these groups determining the microtubule binding affinity of Tau. In
a healthy brain, phosphorylation is tightly regulated, and modification of Tau
affinity to microtubules (Mandelkow et al. 1995), with phosphorylation of S214 (Biernat et al. 1993), S262
(Scott et al. 1993), and S256 (Schneider et al. 1999) significantly lowering
affinity to microtubules.
B. Membrane-less Organelle Formation
There exists a body of research that implies that before Tau forms its quaternary structures, there
is a transition-state called liquid:liquid phase separation (LLPS). LLPS is the formation of membranelles
organelles inside of cells. Like beads of oil that form in water, macromolecules can form spaces that are
segregated from the rest of the cell. A protein phase separates when it is the most thermodynamically
favorable state, and as such is dependent on protein/solution and protein/protein interactions (Franzmann
and Alberti 2019). As such, acetylation may potentially affect the rate at which proteins phase separate by
changing the total charge and protein/protein interactions.
It has been shown in in vitro studies that modifications to Tau that mimic disease-like versions of
the protein increase the rate of phase separation (Kannan et al. 2020). In the same study, phase separated
modified Tau has been seen to affect other soluble Tau protein in solution, increasing the rate of protein
seeds that cause other proteins to become toxic, and the formation of pathogenic Tau that is seen before
NFTs.
III. Post-Translational Modifications
Post-translational modification (PTMs) is one of the methods that the body employs to be able to
regulate protein structur
Voet et al.
like oxidative stress (Wall et al. 2012
protein has been produced by the ribosome, enzymes are able
N or C terminus of a protein, or also on an amino acid residue (Voet et al.

A.Ubiquitination
Ubiquitination is a PTM that is a key event in the degradation of proteins by the proteasome, with
the system that includes it being called the ubiquitin proteasome system (UPS). Misfolded, degraded, or
otherwise nonfunctional protein are designated through this adenosine triphosphate (ATP) dependent
method (Ciechanover 1998). Ubiquitination happens with three enzymes, ubiquitin activating enzyme (E1),
ubiquitin conjugating enzyme (E2), and ubiquitin protein ligase (E3) (Pickart and Eddins 2004). These three
enzymes working in tandem result in mono-ubiquitination, but normally Tau is polyubiquitinated before
being recognized by the 26s proteasome and degraded (Babu et al. 2005). Polyubiquitination of Tau is
catalyzed by CHIP with E2, and E3 provides specificity of the polyubiquitination (Galves et al. 2019). E3
creates an isopeptide bond between a lysine on Tau and the C-terminus of ubiquitin, so modifications of
lysine residues in Tau may inhibit ubiquitination (Callis 2014).
However, instead of leading to the degradation of Tau, in PHFs found in AD brains Tau is highly
ubiquitinated (Wang et al. 1991), implying that there is some connection with ubiquitination of Tau and its
aggregation. Interestingly, most of the Tau that is found in AD brains is mono-ubiquitinated instead of
polyubiquitinated (Cripps et al. 2006)
B. Phosphorylation

9

Phosphorylation is one of the most common and useful PTMs that can be applied to proteins. It is
a reversible modification that activates or deactivates proteins (Cohen et al. 2002) Tau is a phosphoprotein;
its function is modulated through the presence of phosphate groups, and it contains 85 potential serine,
threonine, and tyrosine sites available for phosphorylation.
Tau is phosphorylated by many kinases, but they can be summarized into three main groups. These groups
are the proline directed kinases (Hanger et al. 1992), non-proline directed kinases (Hanger et al. 2007), and
tyrosine kinases (Williamson et al. 2002). With phosphorylation being a reversible modification, there is
also a group of phosphatases that dephosphorylate Tau, such as protein phosphatase-1, -2A, and 5 (Liu et
al. 2005)
Dysregulation of phosphorylation is seen in multiple neurodegenerative diseases. Normally, Tau is
a disordered, highly soluble protein, but in various ND it exists in a highly ordered, insoluble, aggregated
form. Phosphorylation is implied to be an upstream event of Tau aggregation, and hyperphosphorylated
Tau aggregates spontaneously in vitro (Alonso et al. 2001), while dephosphorylation of soluble Tau from
an AD brain restores native function of the protein (Iqbal 1998). Soluble Tau contains 10 phosphorylation
sites when taken from a normal brain (Hanger et al. 2007), while Tauopathy brains show 16 phosphorylation
sites (Wray 2008). However, it is currently unknown if it is overall phosphorylation or phosphorylation at
specific sites that causes this toxicity. It has been observed that phosphorylation at specific residues is
sufficient to trigger neurotoxicity in Drosophila (Steinhilb et al. 2007).
Another detriment of hyperphosphorylation is seen when Tau turnover rate is regulated by the
degradation of the protein by the proteasome, and hyperphosphorylation has been seen to almost stop Tau
degradation completely(Poppek et al. 2006). Increasing total protein level also increases the rate of
aggregation within the cell to maintain equilibrium, so inhibition of degradation directly leads to more
aggregates.
C. Acetylation
Acetylation is a modification that can occur post-translationally or co-translationally. Tau displays
both N-terminal acetylation, and the ability to have some of its lysine residues acetylated (Min et al. 2010).
Most of the lysine that have been shown to undergo acetylation are present in the MBD of Tau, and
importantly acetylation of K280 is implied to be part of the transition to pathologic Tau by inhibiting
microtubule binding and increasing the rate of PHF formation (Irwin et al. 2012) Unlike the acetylation of
side chains, N-terminal acetylation occurs co-translationally (Dinh et al.2015). Most of the proteins inside
of the eukaryotic proteome are N-terminally acetylated (Arnesen et al. 2009), which implies that there is
some importance in the modification to the native function of a variety of proteins. Core metabolic
processes display similar conservation across the eukaryotic spectrum (Peregom-Alvarez et al. 2009), so it
may have vital importance to the function of proteins in the human body. However, the effects of N-terminal
acetylation vary between proteins, which increases the difficulty of studying the modification.
Inside of the body, Tau is acetylated by the proteins p300 or the CBP acetyltransferase, and the
acetyl group is sourced from acetyl-CoA (Min et al. 2010). Tau also displays some acetyltransferase activity,
with some cysteine residues within the MBD (C291 and C322) showing the ability to acetylate Tau intra
and inter molecularly. (Cohen et al. 2013)
There are two main consequences of acetylation that Tau is expected to exhibit. The first of these
is the decrease of recognition by Tau by the UPS (Min et al. 2010). The lysine residues in Tau that have
been observed to be regularly acetylated overlap with the residues that can be polyubiquitinated (Morris
2015), or the residues that work to designate Tau to be degraded. If the protein is not properly degraded and
total Tau levels are increased, the amount of aggregates present will increase as well to maintain an
equilibrium. Acetylation is also believed to inhibit native Tau-microtubule interactions. (Cohen 2011)
Because acetylation works to neutralize the positive charge that is normally on the MBD of Tau, it impairs
the ability of Tau to bind to the negatively charged surface of microtubules (Luo et al. 2014).
D. Effects of Aging on Protein Regulation
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The human phenotype is plastic, as an individual ages, the functions of their body change as well.
Going along with the main risk factor of neurodegenerative diseases being age, the function and number of
various proteins and enzymes in our bodies decrease with age in accordance with decreased metabolism.
Proteins lose the ability to be regulated reliably with age, and acetylation is one such process whose
prevalence changes with age (Lu et al. 2011). Further studies into the effects of N-terminal acetylation can
look at the relevance of this modification in the aging body.
IV. Proteinopathies and aggregation
Normally within a healthy brain, there are a wide variety of proteins that exist in their monomer
form in a physiological and functional state. However, due to some cause these proteins undergo a
conformational change and begin to create small oligomers and then eventually higher order structures
within the brain. Proteinopathies are a family of diseases that are caused by irregular protein folding, and
therefore irregular protein dynamics inside of the body. This irregularity disrupts the proteostasis network
within the body. Within the body the proteostasis network is this tightly regulated system that allows the
body to synthesize, distribute, and degrade proteins throughout the cytoplasm into locations where the
protein is needed (Bayer 2015). Although Tau is a protein that does not have a tertiary structure, it is able
to form these dangerous higher order structures. In some neurodegenerative diseases, when there is a
stockpile of hyperphosphorylated Tau protein, it will spontaneously form insoluble aggregates known as
paired helical filaments (PHFs) (Lee et al. 2001). Owing to its cysteine residues inside of the microtubule
binding domain of the protein, Tau can spontaneously aggregate (Sahara et al. 2007). Although normally
Tau can be disposed of by the proteosome and would be taken care of once it loses its function, aggregation
lowers the ubiquitination of the protein and as such the aggregated protein cannot be disposed of and
accumulates (Poppek et al. 2006).
A. Aggregation and Aggregates
Tau aggregates are called paired helical filaments because upon aggregation the proteins obtain a
cross- -sheet conformation with parallel, in-sheets that run perpendicular to the long axes of the
filament, resembling two protofilaments wound around each other. (Sawaya et al. 2007). The protein can
form aggregates with alternative conformations (Maeda et al. 2007), but the PHFs are the most prominent
aggregate seen, and resemble mature Tau that is recovered from AD brains (Berriman et al. 2003).
The aggregation of Tau in vitro is a reproducible event, so there is a secondary sequence
characteristic that is driving Tau aggregation. Indeed, in a normal cell, Tau aggregation is driven by a
hexapeptide motif (306VQIVYK311) contained in the third repeat region of the protein (Bergen et al. 2000).
Tau, and circular dichroism and
Fourier transformation Infrared spectroscopy displays that in conditions of self-assembly that this region
et al. 2000). It is believed that PHF formation is influenced by this
sequence (Meraz-Ríos et al. 2010)
B. Toxicity of Aggregates
One of the common aspects of various neurodegenerative diseases is the toxicity of the aggregated
proteins that are seen within the diseases. There is some controversy as to whether the NFTs are a
contributing factor to neurodegenerative illness or simply an effect of them, with some research displaying
soluble Tau as the culprit behind neurotoxicity, (Crimins et al. 2012) (Yoshiyama et al. 2007), but there is
a gap in knowledge in the pathogenic mechanism of soluble Tau, which makes it difficult to study. However,
although there are no Tau mutations that can be linked to an ND like AD, studies done on frontotemporal
lobe degeneration have found >30 mutations in the MAPT gene that enhances aggregation and
neurodegeneration (Swieten and Spillantini 2007). Interestingly, as well, in fetal human's Tau is
hyperphosphorylated at rates like those seen in AD, but the protein does not show increased levels of
aggregation (Kenessey and Yen 1993). Fetal Tau is comprised entirely of the third repeat region of the
protein and has a lower rate of aggregation because of it. This implies that hyperphosphorylation and its
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resulting loss of microtubule binding activity are not sufficient to cause a Tauopathy, and there are other
factors that are involved in the illness's cascade.
The toxicity of Tau aggregates is observed in neurons where it is most abundant in the body. Upon
emergence of disease, Tau can no longer properly bind to microtubules and cannot strengthen axons at an
acceptable rate, leading to neuronal death (Wang et al. 2016). Native Tau function is vital for normal brain
function.
Aggregated proteins have also been observed to
increasing the spontaneous aggregation rate once some protein has become misfolded, or if a misfolded
protein is introduced to another environment. This is like prion diseases, where the misfolded protein can
become a template for the other proteins in a cell (Walker 2013). Tau has shown this prion like ability,
being able to propagate itself through adjacent cells (Dujardin and Hyman 2019). However, the mechanism
by which Tau does so is unknown, and it does not propagate at a rate like other prions, so the protein is not
considered a prion. Tau has also not proven itself to be infectious (Bloom 2014), so the protein is considered

C. Oligomeric Species of Tau
Oligomers of a protein are protein conformations where there are a few repeating units of a protein
put together. Although aggregates are looked at as the main culprit of cytotoxicity in cells, oligomers are
another form of the protein that has been shown to be pathogenic. It has been seen that oligomeric species
of Tau are an intermediate between the monomeric form of the protein and higher order species of Tau
(Lasagna-Reeves et al. 2012). Higher order aggregates of the protein are insoluble and lose their native
function, so the increase of an intermediate state would also increase the level of aggregates in cells. But
even Prefibrillar Tau oligomers accumulating in the cell shows cognitive deficit that mirrors AD symptoms.
(Mufson et al. 2014).
V. The Effects of Protein N-terminal Acetylation
This project aims to look at the changes N-terminal acetylation has on Tau structure and function.
Although it has previously been displayed that Nprotein (Derisbourg et al.
of the protein, so there is a relative lack of information concerning this PTM. Analytical techniques such as

A. Process of N-terminal acetylation
N-terminal acetylation involves the transfer of an acetyl group from acetyl coenzyme A to the alpha
amino acid of a protein. Unlike most protein modifications, N-terminal acetylation is an irreversible
modification. N-terminal acetylation occurs as the protein is being synthesized and is catalyzed by Nterminal acetyltransferases(NATs) associated with ribosomes (Gautschi et al. 2003). There exists a variety
of NATs in eukaryotic systems, ranging from NatA-NatF, and each is composed of distinct subunits,
granting them the ability to selectively acetylate proteins depending on their initial amino acid
sequences(Polevoda et al. 2009).
B. Effect of N-terminal acetylation
-90% of proteins that are produced in the body
et al. 2016), it is not well understood what these changes do to the structure or the
function of a protein. It has been hypothesized that N-terminal acetylation works to stabilize protein by
blocking amino acids that could be marked for ubiquitination (Hershko et al. 1984), there has not been any
proteins found that are degraded through N-terminal ubiquitination when lacking acetylation. Although an
unacetylated N-terminus may lead to destabilization in a manner that is independent of the ubiquitin
degradation pathway (Pena 2009). In humans, having a deficiency of NATs results in Ogden syndrome.
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Children with Ogden syndrome are born with postnatal growth failure and pass within the first 1-2 years of
life (Myklebust et al. 2015).
Evolution is an efficient process, so changes that are not necessary to the function of a protein are
usually phased out, either to make space for a more efficient alteration or because the alteration is not
necessary. Although higher eukaryotes express more NATs and as a result have a higher percentage of Nterminally acetylated protein, when looking at lower eukaryotes such as Saccharomyces cerevisiae exists a
good deal of homology with the biological machinery of N-terminal acetylation (Polevoda 1999). Because
acetylation is a highly conserved method of protein modification, it has some sort of relevant function
in maintaining the function of proteins within the body .Additionally, Tau and other microtubule binding
proteins contain an extreme N-terminus that is conserved in metazoans (Sündermann et al. 2016), but the
role that this domain plays is unclear. There is some evidence that the N-terminus may fold over and be
found around the hydrophobic core of the protein (Dulak et al. 2018). Folding in proteins is driven by the
solubility of its amino acids in water (Zhou and Pang 2018). Changing the charge on the free amine group
of an N-terminus to the neutral charge of an acetyl group has potential to change the way that
extreme
N-terminus is oriented in solution.
Affecting overall stability of the protein may have an effect on LLPS formation, as previously it
has been displayed that unstable hyperphosphorylated species of Tau are both linked with disease and
increase LLPS transition rate (Kanaan et al. 2020). Also, one aspect driving LLPS formation is electrostatic
interactions between proteins (Boyko et al. 2019), so the change of charge could affect the rate at which
LLPS and in turn oligomers of Tau form.
group the free amine end of a protein changes the overall charge of a protein, affecting its electrostatic
forces and make change how it interacts with itself. Although many proteins in the human body are seen to
have this modification, the alteration that occurs when they are acetylated varies. Looking at other
intrinsically disordered proteins for inspiration such as - synuclein has its aggregation kinetics altered by
N-terminal acetylation(Watson and Lee 2018). But
The hypothesis of this project is that N-terminal acetylation is a post-translational
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MATERIALS AND METHODS
Recombinant DNA
HB45: Nat A DNA in Pet15 Vector and Chloramphenicol Cassette
HB76: Full length Tau DNA in PET22 vectors with C-terminal His-tag and Ampicillin Cassette
Transformation of Plasmid into Competent Cells
Competent DE3 E. coli

s were

before being heat shocked at 37°C for 90 seconds. After heat shock return mixture was returned to ice and
to 37°C. Plates
contained appropriate antibiotic concentrations (2.9 mM ampicillin or 0.77 mM for chloramphenicol).
Plates were inverted and then incubated overnight at 37°C or 48 hours at room temperature.
Large Scale Inductions
After successful bacterial transformation colonies were taken and put into 50 mL of LB with appropriate
antibiotic (final concentrations 2.9 mM for ampicillin and 0.77 mM for chloramphenicol). After overnight
incubation at 37°C, 5 mL of media was taken and placed into 4 1 L flasks of LB with appropriate antibiotics.
Solution optical density (O.D) was measured at 600 nm until it reached between 0.2 and 0.4. Protein
production in cultures were then induced with IPTG (0.8 mM final concentration) and left to incubate in
shakers at 37°C for 24 hours.
Harvesting Large Scale Inductions
After induction, liquid cultures were moved to 250 mL centrifuge tubes and centrifuged at 10,000 RPM in
resuspended in 75 mL of water. In same centrifuge tubes, remaining liquid culture was added. After
exhausting liquid culture from 1 L flasks, begin to combine resuspended pellets into 2 250 mL centrifuge
tubes. This process was repeated until all culture was in 2 250 mL centrifuge tubes. Supernatant was again
discarded, and cell pellets were stored at -20°C.
Protein Purification
Frozen pellets were thawed and resuspended inside of centrifuge tubes with lysis solution(50 mM TrisHCL pH 9.0 150 mM
with 15 seconds of on time and 15 seconds of off time for a total time of 1 minute and 30 seconds. Pellets
were subjected to two rounds of sonication with around 2 minutes in ice between sessions. After sonication
pellets were moved to 90°C -100°C water bath for 15 minutes. After water bath, pellets were moved back
to ice for 15 minutes. After resting on ice pellets were centrifuged for 45 minutes at 18,000 RPM at 4°C in
-micron filter into a 50 mL conical tube, and
precipitate was discarded.
software was began. The sample valve was placed into the 50 mL conical tube containing protein, and inlet
valves were set up with one having buffer A (50 mM Tris-HCl 9.0 150 mM NaCl) and another with buffer
B (50 mM Tris-HCl 150 mM NaCl 500 mM Imidazole).
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After setup, HIS-tag purification protocol was started. Sample volume was set lower than actual sample
volume as to minimize the possibility of air entering FPLC. Fractions were automatically collected, and
protein concentration was measured using UV absorbance. Protein solution was loaded onto column, and
then wash was done with 100% buffer A for 10 column volumes. No fractions of interest are collected
during this stage. Elutions were done with a linear increasing gradient of buffer B culminating in 100%
buffer B over 5 column volumes. Fractions were divided into 5 mL each during elution. Fractions during
elution stage of purification with high UV absorbance were denoted as samples containing Tau and
collected, while other samples were discarded.
Protein concentration was then measured at 280 nm. If protein concentration was over 5 mg/mL it was
diluted to 5 mg/mL an
nitrogen, and stored at -80°C. If below 5 mg/mL, protein was concentrated in 5 kDa molecular weight cutoff
Vivaspin® 20 Centrifugal Concentrator overnight at 15,000 RPM at 4°C overnight. On the following day
protein was collected from concentrator and diluted to 5 mg/mL, and frozen with protocol outlined
previously.
SDS-PAGE Visualization
Protein samples were run on 8% SDS-

ed Protein Ladder,

Tris-Glycine SDS buffer at 100 volts for 10 minutes, and then 200 volts until dye front runs off gel. Gels
were stained using standard Fairbanks procedure.
Native PAGE Visualization
nM
buffer (30 mM Tris 30 mM PIPES 10 mM EDTA), for 3 hours at 4°C at 100 volts, or under the same
conditions at 30 mAmperes. Gels were stained with normal Fairbanks procedure.
Western Blot
TransOAc pH 8.8 0.92 M Glycine 0.35 mM SDS) for 2-3 minutes. Immun-Blot® Low Fluorescence PVDF
Membrane was placed in methanol until translucent and then transferred to tray with SDS transfer buffer
and allowed to equilibrate for 2-3 minutes. Sandwich was assembled with gel from SDS page in cassette
and ran on Transansfer protein was blocked with
After overnight blocking, membrane was rinsed for 5 minutes with 0.1% TSBT (20 mM Tris 150 mM NaCl
0.1% Tween 20). Membrane was then washed with a 1:8,000 dilution of Tau Ab-3 rabbit polyclonal
antibody in 1x TBS (50 M Tris 150 mM NaCl) for 45 minutes. After primary antibody wash, membrane
was washed 3 times with 0.1% TBST for 10 minutes. Then, the membrane was tagged with either a 1:5,000
dilution of Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP for chemiluminescence or a 1:500
dilution of Goat Anti-Rabbit IgG H&L (DyLight® 650) for fluorescent studies. Both antibodies were
diluted in 1x TBS.
After secondary antibody tagging membrane was washed 3 times for 5 minutes each with 0.3% TSBT (20
mM Tris 150 mM NaCl 0.3% Tween 20), and then for another 3 times for 5 minutes with 0.1% TSBT. For
chemiluminescence appropriate amounts of ECL reagent was added to cover membrane. Both membranes
were visualized using Azur
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RESULTS
Establishing Double Plasmid Transformation Efficiency and Protein Expression
My first goal was to establish the effectiveness of transforming two plasmids with two different
selection markers in E. coli. To accomplish this, E. coli colonies were selected on LB plates with both
ampicillin and chloramphenicol. Although growth on the plate was less than what would normally be
expected from a culture (Fig. 1A), any growth on the plate indicates that the double transformation was a
success, and that it can be moved onto a larger scale system.
Following the successful growth on agar, bacterial colonies from these plates were taken and the
protein produced and purified from them was visualized on SDS-PAGE. The additional acetyl group on the
modified protein Tau will alter its migration when resolved by SDS-PAGE when compared to the
unacetylated protein, which is normally seen at around 75 kDa. This change in migration is observed by
SDS-PAGE (Fig 1B) where the major protein band from a purification of acetylated Tau runs higher than
the unmodified protein.

Purification of Tau/Acetylated-Tau from E. coli.
After confirming that the transformation and Tau expression was successful, I then scaled up the
expression cultures to produce larger amounts of pure Tau. From a culture that was taken from a successful
transformation, samples were taken before and after induction with IPTG. A large band at 75 kDa appears
after Tau induction (Fig 2A), indicating successful start of protein production. Producing protein with a Cterminal poly-histidine motif enables purification from lysed cell culture through nickel affinity
chromatography. Each step (Fig. 2A) taken in the purification looks to further isolate Tau from unwanted
products of bacterial production, such as cell debris or miscellaneous proteins. The product of this isolation
is mostly pure Tau protein (Fig. 2B and 2C).
One benefit of working with an intrinsically disordered protein is the ability to boil samples. Like
boiling egg whites, proteins that are exposed to high-temperature environments unfold and lose their
solubility, crashing out of solution. However,
status as an intrinsically disordered protein means that
we can boil it and it remains soluble in solution. Many proteins that E. coli produce are precipitated during
this boiling process, and you can see that after boiling the major band that corresponds to Tau at 75 kDa
remains with other disappearing. Following boiling, I used FPLC and nickel affinity chromatography to
isolate Tau from solution. I measured the protein content of the flowthrough by measuring UV absorbance
of sample (Fig. 3A and 3B), leading me to collect fractions from elution steps that have high absorption
values, such as 7-11 (Fig. 3A) for full-length Tau and fraction 9 (Fig. 3B) for acetylated Tau. Total protein
content correlates to the integral of the fractions that are being collected, so although both purifications
loaded similar amounts of sample onto column, the full-length Tau has an area of 3,733 mAU while
acetylated Tau has an integral of 869 mAu. The full-length Tau sample provided around 4 times as much
absorbance. This is believed to be a limitation of the double-transformation system, producing significantly
less protein when compared to a single transformation.

Determining optimal storage conditions for purified Tau
Although we can produce large quantities of protein with every successful induction, my next goal
was to establish proper storage conditions for Tau. Acetylated Tau in particular produces more dilute
fractions than full-length Tau because of the reduced total protein production. My goal was to concentrate
Tau to 5 mg/mL, and protein fractions that did not meet this were concentrated via spin concentrator tubes.
Increase of total protein in solution was seen after overnight concentration. (Fig. 4A)
To store protein for extended periods of time, special measures must be taken, but they each have
their trade-offs. Concentrated full-length Tau samples from a purification were diluted and treated to a
variety of conditions over 48 hours to view degradation of protein (Fig. 4B). Tau that was frozen in liquid
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nitrogen and then stored at -80°C showed the least amount of degradation. Although the sample from
protein precipitate shows low amounts of degradation as well, the process to precipitate proteins is more
time-consuming, and results in some protein being lost. Also, although storing with glycerol does also
prevent a good deal of degradation, introducing glycerol to assays can cause issues, so working with
minimal or no amounts is ideal. Because of its ease of use and effectiveness, the liquid nitrogen method
was determined to be optimal for long-term storage.
Visualizing Tau Oligomers Found in Solution
While SDS-PAGE resolves denatured proteins, this means that higher-order structures or
electrostatic interactions between proteins in sample cannot be visualized. My goal is to determine changes
electrophoresis to observe samples in their native
states. Protein was successfully resolved by native PAGE (Fig.5A) and I experimentally determined optimal
conditions to maximize resolution. Varying concentrations of Tau were run to determine the best
concentration of protein to use (Fig. 5B), and 2.5 mg/mL provided sufficient resolution. I next wanted to
optimize the resolution of the separated Tau oligomers and my first task was to vary the concentration of
acrylamide in the native gel. While lower percentages allow larger protein complexes into the gel, there is
significant loss of resolution. I experimentally determined with Tau that 10% acrylamide was sufficient for
the native PAGE (Fig. 5C). Another variable that affects resolution is the electrical current running through
the gel. I initially ran gels under constant, however this did not sufficiently resolve oligomeric complexes
and resulted in smears. I next set the conditions to constant amperage, which would result in a consistant
current as the proteins migrant within the gel. Running the gel at a constant amperage with all other
conditions equal provided a gel with increased resolution. With a 10% gel and a constant amperage I was
able to resolve monomers and dimers of Tau (Fig. 5D)Tau. While these are preliminary pilot experiments,
being able to separate proteins based on their molecular weight allows me to view dimers, trimers, and
other higher order structures for to quantify in future experiments.
Visualizing Protein by Western blot
Visualizing proteins by native gel electrophoresis requires a significantly higher concentration of
protein and we may not be able to visualize oligomers that are at low abundance. To address this, we utilized
Western blotting using a conformation agnostic anti-Tau antibody to visualize all species of Tau found in
solution. Full-length Tau that was purified and resolved by SDS-PAGE was transferred to a low
fluorescence PVDF membrane. The membrane was tagged with a primary antibody of rabbit anti-Tau and
followed with a goat anti-rabbit antibody conjugated with HRP for chemiluminescence. After tagging of
secondary antibody the membrane was covered in ECL reagent. For fluorescence, instead of the goat antirabbit conjugated with HRP, the membrane was instead tagged with a goat anti-rabbit antibody that was
tagged with a fluorescent marker.
Tau was visualized successfully utilizing secondary antibodies by both chemiluminescent (Fig. 6A)
and fluorescent methods (Fig. 6B). Although the SDS-PAGE that the Western blots are preliminary, I was
still able to visualize Tau using two separate methods.
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Figure 1: Protein expression gel of Full-Length Tau (FLT) and Acetylated Tau (AT) A.
Schematic Diagram of Double Transformation with Agar Plate Confirming Transformation
Two plasmids can be inserted into Escherichia coli in order to modify protein in a bacterial
expression system. Agar plate contains antibiotic selecting for each plasmid. B. Full Length-Tau
and acetylated Tau Expression Gel 8% SDS PAGE ran to visualize the migration of Nterminally modified Tau compared to unmodified. Stained with Coomassie blue.
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Figure 2: Purification of Tau/Acetylated-Tau from E. coli. A. Schematic Diagram of
Purification Process Schematic showing pictures from each step of nickel purification.
Displaying cells post lysis, post boiling, nickel affinity column, and protein in concentrator tube.
B. Purification of 4L Induction of FLT. 8 l of sample from various stages of nickel affinity
chromatography purification were ran on 8% SDS PAGE and visualized with Coomassie blue
staining. C. purification of 4L Induction of AT. Like B except A-Tau production is being
induced
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Figure 3: Chromatograph from FPLC Purification of Tau Pellets A. Chromatograph from
an FPLC Nickle Purification of 4L of FL Tau Approximately 60 mL of protein rich fluid
acquired from 4L induction was ran on FPLC column. Weakly binding protein was washed off
column with low salt buffer. Elution of protein bound to column occurred on increasing imidazole
gradient with initially none in solution until 500 mM imidazole was reached. Fraction collection
was automated and fractions 8-11 were collected for future experiments. Relevant peaks were
integrated. B. Chromatograph from a Nickle Purification of 4L of A-Tau. A chromatograph
from a 4L induction of A-Tau. Like D, but from an A-Tau preparation.
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Figure 4: Determining optimal storage conditions for purified Tau. A. Concentrating Eluted
Protein Purified Tau samples that had a concentration less than 5 mg/ml were concentrated
overnight and 8 l of each sample was ran an on 8% SDS PAGE and visualized with Coomassie
blue staining. B. Protein Storage Stress Test Tau aliquots were kept in outlined conditions over
4 days and 8 l was ran on 4-20% SDS PAGE visualized by Coomassie blue staining. Samples
were run at a 1:10 and then 1:20 dilution. Lanes 1-6 were stored at -800C
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Figure 5: Optimizing Native PAGE Conditions to Visualize Tau Oligomers. B. 5%
Acrylamide Native PAGE 5% Native PAGE of 5 mg/mL visualized using Coomassie blue. 15 l
of each sample was ran in each lane. B. 5% Acrylamide Native PAGE 5% Native PAGE of of
serially diluted Fl-Tau Fl-Tau visualized using Coomassie blue. 15 l of each sample was ran C.
10% Acrylamide Native PAGE 10% Native PAGE of 2.5 mg/mL Fl-Tau visualized using
Coomassie blue. 15 l of each sample was ran in each lane D. 10% Acrylamide Native Page Ran
at Constant Amperage 10% Native PAGE of 2.5 mg/mL Fl-Tau visualized using Coomassie blue.
15 l of each sample was loaded, gel was run with updated protocol.
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Figure 6: Western Blots of Purified Tau Samples A. Chemiluminescent Western Blot of Tau
10% SDS PAGE of Tau was ran and transferred to low-fluorescence PVDF membrane. Membrane
was tagged with HRP and ECL reagent was applied to membrane before imaging. B. Fluorescent
Western Blot of Tau 10% SDS PAGE was ran and gel was transferred to low-fluorescence PVDF
membrane. Membrane was tagged with Fluorescent secondary antibody and imaged.
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Discussion
Producing Post-Translationally Modified Protein in a Bacterial Expression System
Bacterial expression systems are a popular choice for recombinant protein production. Bacteria are
easy to grow, allow for high yield, and are relatively in expensive. A continually replenishing culture of
stock bacteria for protein production can be modified to create a protein of interest through transformation
of a plasmid that contains the genetic information necessary to create it. When undergoing environmental
from its environment. However, although bacteria can produce protein from recombinant DNA and create
protein that they normally cannot, they are unable to perform eukaryotic specific post-translational
modifications. Bacteria do not innately possess the necessary eukaryotic enzymes to post-translationally
modify a protein at a rate that is relevant for research (Macek et al. 2019). However, with the introduction
of a second plasmid the bacteria can then modify protein at a level where experiments can be done. This
second plasmid allows the bacteria to create N-terminal Acetyltransferases (NATs), which catalyze the
addition of an acetyl group to the N-terminus of Tau co-translationally (Starheim et al. 2012).
Although bacteria have short generation times and will quickly dispose of any DNA that is deemed
unnecessary for survival because of the error prone nature of their replication, (Tippin et al. 2004),
controlling for bacteria that have both plasmids present is a simple procedure. Each plasmid contains an
antibiotic resistance gene that allows bacteria to grow in selective culture. In a double transformation system,
each plasmid contains a different antibiotic resistance gene, and a bacteria must keep both to be able to
survive in the selective media that it is placed in. However, the increased amount of antibiotics appears to
result in slower bacterial growth and less total protein production when compared to a single transformation
system.
The flexibility of this system allows for the introduction of one plasmid for production of
unmodified Tau or a second plasmid to create the acetylated form of it. Also, because the production of
protein is inducible through a modified lac operon instead of being constantly active in this system, the
bacteria can grow normally until reaching a suitable concentration of protein production. Production is
- d-1-thiogalactopyranoside (IPTG), a mimic of allolactose that bacteria are unable
to metabolize and as a result concentrations in culture remain constant.
Isolating Protein from Cell Lysates
When implementing a bacterial expression system, the protein that is produced must be isolated
from bacterial cell lysates and culture. Although this may not be necessary when performing Western blots,
testing for protein expression, or ligand binding studies, structural work on protein requires pure samples.
While Tau does not have a fixed 3D structure, NMR (Nuclear Magnetic Resonance) can allow some
visualization of its 3D structure (Gibbs et al. 2017).
Because Tau is an intrinsically disordered protein, it can withstand conditions that cause other
proteins to denature. This allows us to boil our whole cell lysates to cause other bacterial proteins to
precipitate out of solution, and to deactivate bacterial proteases that may degrade our protein (Livernois et
al. 2009). Tau remains soluble in solution, and we can move onto nickel affinity chromatography to further
purify our sample. Tau expressed by the bacteria has a polyhistidine tag on its C-terminus, a motif that
allows the protein to be separated from whole cell lysates by granting the protein a high affinity to nickel.
By passing our boiled samples in a high-pressure system through a nickel column, we can bind Tau to the
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column. Proteins lacking the poly-histidine tag will be unable to bind to the column and will simply pass
through the column. Following this, we can pass a solution of imidazole (the functional group of histidine)
through the column to dislodge the Tau and collect a pure sample of the protein. Nickel affinity
chromatography shows good yield of protein, and results in relatively pure samples (Bornhorst and Falke
2010). The poly-histidine tag is placed on the C-terminus of a protein because proteins are normally
translated from N-terminus to C-terminus, so protein with high affinity to the column should be complete
Tau portions.
When attempting to perform experiments involving protein one major concern involves the storage,
purification, and other miscellaneous processing of the protein. Although Tau is an intrinsically disordered
protein and is more stable at room temperature than other proteins because there is no worry about loss of
3D structure (Uversky 2015), it can still undergo degradation if kept in harsh conditions or freeze-thawed
excessively. Because of this, proper storage of the protein is integral to performing future experiments. It
is typical to store protein in a 80°C freezer for long term storage but freezing the protein while minimizing
degradation is an issue.
Acetylated Tau in particular produces an elutant that is too low in concentration to be able to do
many experiments with. Although theoretically larger scale inductions could be done it is unclear if this
would increase the protein concentration to a usable level. Proteins were instead concentrated using a
centrifuge tube with a polyethersulfone (PES membrane that retains molecules of a certain molecular
experiments.
Visualizing Protein
After production of the protein, a key step in experiments is simply to visualize the protein that has
been produced. Because we are attempting to look at the effect of a post-translational modification of a
protein or the oligomerization state of the protein, two obvious choices for visualization are Western
blotting and native PAGE.
Western blots are a powerful method of being able to view protein. It is an immunoassay detecting
protein that has been fixed onto a membrane with the two antibodies and is highly specific in nature. The
first antibody to bind is the primary antibody. Primary antibodies are capable of binding to specific proteins
that are in different physical states, such as selectively binding to either acetylated or unacetylated Tau
(Saper 2009). Secondary antibodies then go on to bind to these primary antibodies and allow us to visualize
our samples using either chemiluminescence or fluorescence. Although the SDS-PAGE that the Western
blots were taken from did not run evenly, it is unimportant for the visualization of the protein. The increased
resolution from a cleanly running PAGE was not relevant, as any signal shows successful secondary
antibody binding and indicates a successful Western blot.
Native PAGE is another method in visualizing protein that has been produced. This is a nondenaturing gel that allows for separation of a protein based off of its mass, charge, and structure. While
developing the protocol for native PAGE, many factors were changed about the composition of the gel and
the running conditions. Gel acrylamide percentage is one such factor. Increasing acrylamide percentages
decreases pore size after casting and allows for better visualization of small proteins because larger proteins
become stuck in the smaller pores. 10% acrylamide concentration appears to give acceptable resolution.
Another factor that was viewed was with the decision to either make the voltage or the amperage while
running the gel the constant. Although granting good resolution, the heat from running a gel at constant
amperage results in uneven running and makes interpreting results difficult, protein was able to be
visualized on the gel.
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Future Directions
Now that there is a rudimentary understanding of the conditions that can be used to run a native
PAGE and even the presence of some high running bands that are possibly species of Tau that have
spontaneously aggregated in solution, there is the possibility of performing blue native PAGE. Because we
are seeing some bands that are running higher than the most concentrated bands in our sample, there is
reason to believe that these bands are higher-ordered structures. The only protein that is being ran in high
enough concentration to be visualized on the native PAGE is Tau, and Tau has been known to spontaneously
aggregate in solution. Although further confirmation is needed, it seems that it is possible to view aggregates
with native PAGE. Blue native PAGE is a non-denaturing method of separating protein, there exists a
variation of the method that allows for observation of protein-protein dynamics and separation of protein
based on their oligomerization state (Witting 2006). This method of detection would allow for definitive
identification of the higher running bands and would allow us to use blue native PAGE as a method to
quantify aggregation.
Western blotting allows for selective assessment of protein samples. Fluorescent staining is the
avenue to which the protocol is being moved to. Chemiluminescence relies on an enzyme-substrate reaction
to produce light and because of this is hindered due to the varying rates of reaction kinetics, not allowing
for a quantitative analysis of protein in solution. This makes it useful for a very sensitive method of protein
identification but limits its other applications. Fluorescence on the other hand is directly proportional to the
total amount of protein that is present on the gel. This allows for fully quantitative calculations done with
the amount of light emitted, and because each antibody emits light in a specific wavelength multiple
antibodies can be used for complex assays (Gingrich et al. 2000). These assays can look at acetylated vs
unacetylated ratios in human neuronal tissue to see acetylation rates in patients suffering from ND.
While the protein samples that are produced from the nickel affinity chromatography are relatively
pure, to perform high resolution structural analysis of a protein such as with x-ray crystallography protein
purity should reach at least 95% (Kim et al. 2009). Although it is possible to simply pass the protein through
the nickel column an additional time to purify it further, proteins that bind non-specifically to the nickel
column may be impossible to remove from solution. Other forms of chromatography may be employed to
narrow down conditions to a point where Tau is more concentrated in solution. Ion exchange
chromatography (IEX) is one such method of separating proteins based on another physical characteristic.
(Jungbauer and Hahn 2009). Using an ionic column instead of a nickel column, and a pH gradient instead
of an imidazole gradient, the protocol for the nickel purification can be easily adapted to this new method.
Gel filtration chromatography is another chromatography method that can separate proteins in solution.
Instead of further purification, this allows for the separation of proteins based off their molecular weights
(Hagel 2001). Concentrations of higher-order structures such as dimers, trimers, or oligomers can be viewed,
and aggregation rate of Tau can be assessed.
Having a reproducible method to create large amount of Tau in both its acetylated and unacetylated
state, it is possible to do experiments that are concentration dependent. Previously experiments involving
liquid-liquid phase separation or aggregation were not possible because they are concentration dependent
(Franzmann and Alberti 2019), but with revisions to our protocol it is now possible to use these experiments.
Although much of the work that was done was simply in the production and purification of the protein, this
is integral to doing more advanced analytical studies with the protein in the future. NMR and X-ray
crystallography require protein in high concentrations and pure samples of protein (Kim et al. 2009), so
structural assessments of the protein in the future need methods such as these.
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If something such as the ability of acetyltransferase to consistently modify protein is affected with
age, this would be a relevant avenue of research. Being able to determine if this decrease in acetylation rate
is an early marker for a Tauopathy could be something that can be used in counseling to begin prophylactic
treatment, or if an individual is known to have some sort of family history of neurodegenerative Tauopathies
that they could be administered a drug to assist in acetylation.
Tau aggregation remains a mysterious part of Tauopathies and other diseases that the protein is
involved in, so further characterization of the structure, the effect that N-terminal acetylation has on the
protein, and how it can interact with itself in solution is critical when considering new effective methods to
combat these illnesses.
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